



EMEA PUBLIC CONSULTATION ON TRANSPARENCY

FVE CONTRIBUTION

Information to be released by the EMEA

FVE strongly recommends that the product information released by the EMEA should - above all - be addressed to the veterinary health professionals.

Members

Austria
Belgium
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
FYROM
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovak Republic
Slovenia
Spain
Sweden
Switzerland
United Kingdom
Yugoslavia

The veterinary drug information as currently presented on the EMEA homepage is a very useful source of information for experts interested in or working in the field of veterinary medicinal products. The presentation of data should be maintained at an expert level. No particular distinction should be made between products intended for use in food producing animals or in companion animals, rather all details, which might be useful for specialists, should be given. This applies to both POMs and non-POMs.

Interaction between CVMP and interested parties

FVE considers that dialogue between CVMP and interested parties could be improved and therefore welcomes the initiative of the EMEA to review the current state-of-play.

FVE experience of CVMP/interested parties meetings is that it is a forum more for reporting than for in-depth discussions. There is thus no real forum to discuss important issues such as guidelines and to allow an exchange of views between the experts of the different sides. The horse 6-month withdrawal period recommendation, the SPC guidelines or the MRL-extrapolation guidelines are such examples where FVE would have liked to have had a more open discussion with the CVMP and its members.

Also, FVE believes that the input of practitioners could also be useful when discussing points such as the conditions of use of a product, the disposal of unused products, the information to be included on the packaging and how this information should be conveyed.

In many Member States, representatives of the veterinary profession are involved to a greater or lesser extent in the evaluation process and such involvement certainly adds value to that process. This also used to be the case in the former CVMP, when interested parties representatives were invited by the European Commission to attend the 'open' sessions of each CVMP meeting.

The inclusion of representatives of the principal interested parties in the recently established EMEA Committee for Orphan Medicinal Products is a recognition that interested parties also have something to deliver and paves the way for a different and more active collaboration between the CVMP and its interested parties.

FVE would therefore be pleased to discuss these ideas further and would certainly welcome proposals to associate more closely the different interested parties in the whole of the work of the Committee for Veterinary Medicinal Products.

Sections

Practitioners
State Officers
Industry and Research
Hygienists

President

Dr K. Simon

Vice-Presidents

Dr O. Bro-Jorgensen
Dr C. Mir
Dr A. W Udo
Dr R. Zilli

Federation of Veterinarians of Europe
rue Defacqz, 1
B – 1000 Brussels

Tel: +32.2.538.29.63 - Fax: +32.2.537.28.28
E-mail: info@fve.org - Internet: www.fve.org